Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Drug repurposing in neurological diseases: an integrated approach to reduce trial and error.

Clout AE, Della Pasqua O, Hanna MG, Orlu M, Pitceathly RDS.

J Neurol Neurosurg Psychiatry. 2019 Jun 6. pii: jnnp-2019-320879. doi: 10.1136/jnnp-2019-320879. [Epub ahead of print] Review.

PMID:
31171583
2.

Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH.

D'Agate S, Wilson T, Adalig B, Manyak M, Palacios-Moreno JM, Chavan C, Oelke M, Roehrborn C, Della Pasqua O.

World J Urol. 2019 May 11. doi: 10.1007/s00345-019-02783-x. [Epub ahead of print]

PMID:
31079189
3.

Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome.

Glaze DG, Neul JL, Kaufmann WE, Berry-Kravis E, Condon S, Stoms G, Oosterholt S, Della Pasqua O, Glass L, Jones NE, Percy AK; Rett 002 Study Group.

Neurology. 2019 Apr 16;92(16):e1912-e1925. doi: 10.1212/WNL.0000000000007316. Epub 2019 Mar 27.

PMID:
30918097
4.

Non-inferiority double-blind randomised controlled trial comparing gabapentin versus tramadol for the treatment of chronic neuropathic or mixed pain in children and adolescents: the GABA-1 trial-a study protocol.

Kaguelidou F, Le Roux E, Mangiarini L, Lundin R, de Leeuw TG, Della Pasqua O, Felisi M, Bonifazi D, Tibboel D, Ceci A, de Wildt SN, Alberti C; GAPP consortium.

BMJ Open. 2019 Feb 20;9(2):e023296. doi: 10.1136/bmjopen-2018-023296.

5.

Pharmacokinetics of plasma infusion in congenital thrombotic thrombocytopenic purpura.

Taylor A, Vendramin C, Oosterholt S, Della Pasqua O, Scully M.

J Thromb Haemost. 2019 Jan;17(1):88-98. doi: 10.1111/jth.14345. Epub 2018 Dec 31.

PMID:
30475428
6.

Authors' Reply to Standing et al.: "Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials".

van Dijkman SC, de Jager NCB, Rauwé WM, Danhof M, Della Pasqua O.

Clin Pharmacokinet. 2018 Nov;57(11):1473-1475. doi: 10.1007/s40262-018-0698-6. No abstract available.

PMID:
30027512
7.

Correction to: Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials.

van Dijkman SC, de Jager NCB, Rauwé WM, Danhof M, Della Pasqua O.

Clin Pharmacokinet. 2018 Aug;57(8):1055-1056. doi: 10.1007/s40262-018-0660-7.

PMID:
29691814
8.

Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials.

van Dijkman SC, de Jager NCB, Rauwé WM, Danhof M, Della Pasqua O.

Clin Pharmacokinet. 2018 Aug;57(8):1039-1053. doi: 10.1007/s40262-017-0614-5. Erratum in: Clin Pharmacokinet. 2018 Apr 25;:.

PMID:
29363050
9.

Analysis of unbound plasma concentration of oxcarbazepine and the 10-hydroxycarbazepine enantiomers by liquid chromatography with tandem mass spectrometry in healthy volunteers.

Antunes NJ, Wichert-Ana L, Coelho EB, Della Pasqua O, Alexandre Junior V, Takayanagui OM, Marques MP, Lanchote VL.

J Pharm Biomed Anal. 2018 Feb 5;149:442-447. doi: 10.1016/j.jpba.2017.11.041.

PMID:
29169112
10.

Challenges in translational drug research in neuropathic and inflammatory pain: the prerequisites for a new paradigm.

Taneja A, Della Pasqua O, Danhof M.

Eur J Clin Pharmacol. 2017 Oct;73(10):1219-1236. doi: 10.1007/s00228-017-2301-8. Epub 2017 Sep 11. Review.

11.

Pharmacokinetic interactions and dosing rationale for antiepileptic drugs in adults and children.

van Dijkman SC, Rauwé WM, Danhof M, Della Pasqua O.

Br J Clin Pharmacol. 2018 Jan;84(1):97-111. doi: 10.1111/bcp.13400. Epub 2017 Nov 7.

12.

Individualized Dosing Algorithms and Therapeutic Monitoring for Antiepileptic Drugs.

van Dijkman SC, Wicha SG, Danhof M, Della Pasqua OE.

Clin Pharmacol Ther. 2018 Apr;103(4):663-673. doi: 10.1002/cpt.777. Epub 2017 Aug 30.

PMID:
28653352
13.

Characterizing QT interval prolongation in early clinical development: a case study with methadone.

Dubois VFS, Danhof M, Della Pasqua O.

Pharmacol Res Perspect. 2017 Jan 24;5(1):e00284. doi: 10.1002/prp2.284. eCollection 2017 Feb.

14.

Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects.

Antunes NJ, van Dijkman SC, Lanchote VL, Wichert-Ana L, Coelho EB, Alexandre Junior V, Takayanagui OM, Tozatto E, van Hasselt JGC, Della Pasqua O.

Eur J Pharm Sci. 2017 Nov 15;109S:S116-S123. doi: 10.1016/j.ejps.2017.05.034. Epub 2017 May 17.

PMID:
28528287
15.

Population pharmacokinetics of NNZ-2566 in healthy subjects.

Oosterholt SP, Horrigan J, Jones N, Glass L, Della Pasqua O.

Eur J Pharm Sci. 2017 Nov 15;109S:S98-S107. doi: 10.1016/j.ejps.2017.05.032. Epub 2017 May 15.

PMID:
28522374
16.

Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients.

Nardotto GHB, Lanchote VL, Coelho EB, Della Pasqua O.

Eur J Pharm Sci. 2017 Nov 15;109S:S108-S115. doi: 10.1016/j.ejps.2017.05.033. Epub 2017 May 15.

PMID:
28522373
17.

Dose optimization of piperacillin/tazobactam in critically ill children.

De Cock PAJG, van Dijkman SC, de Jaeger A, Willems J, Carlier M, Verstraete AG, Delanghe JR, Robays H, Vande Walle J, Della Pasqua OE, De Paepe P.

J Antimicrob Chemother. 2017 Jul 1;72(7):2002-2011. doi: 10.1093/jac/dkx093.

PMID:
28387840
18.

Development and validation of a quantification method for cucurbitacins E and I in rat plasma: Application to population pharmacokinetic studies.

Fiori GML, D'Agate S, Rocha A, Pereira AMS, Della Pasqua O, Lopes NP.

J Pharm Biomed Anal. 2017 Sep 10;144:99-105. doi: 10.1016/j.jpba.2017.02.021. Epub 2017 Feb 20.

PMID:
28274497
19.

Prediction of thyroid C-cell carcinogenicity after chronic administration of GLP1-R agonists in rodents.

van den Brink W, Emerenciana A, Bellanti F, Della Pasqua O, van der Laan JW.

Toxicol Appl Pharmacol. 2017 Apr 1;320:51-59. doi: 10.1016/j.taap.2017.02.010. Epub 2017 Feb 16.

PMID:
28213092
20.

Impact of disease, drug and patient adherence on the effectiveness of antiviral therapy in pediatric HIV.

Piana C, Danhof M, Della Pasqua O.

Expert Opin Drug Metab Toxicol. 2017 May;13(5):497-511. doi: 10.1080/17425255.2017.1277203. Epub 2017 Jan 23. Review.

PMID:
28043170
21.

Translating QT interval prolongation from conscious dogs to humans.

Dubois VF, Smania G, Yu H, Graf R, Chain AS, Danhof M, Della Pasqua O; Cardiovascular Safety Project Team; TI Pharma PKPD Platform.

Br J Clin Pharmacol. 2017 Feb;83(2):349-362. doi: 10.1111/bcp.13123. Epub 2016 Oct 29.

22.

The implications of model-informed drug discovery and development for tuberculosis.

Muliaditan M, Davies GR, Simonsson USH, Gillespie SH, Della Pasqua O.

Drug Discov Today. 2017 Mar;22(3):481-486. doi: 10.1016/j.drudis.2016.09.004. Epub 2016 Sep 28.

PMID:
27693714
23.

How to optimise drug study design: pharmacokinetics and pharmacodynamics studies introduced to paediatricians.

Vermeulen E, van den Anker JN, Della Pasqua O, Hoppu K, van der Lee JH; Global Research in Paediatrics (GRiP).

J Pharm Pharmacol. 2017 Apr;69(4):439-447. doi: 10.1111/jphp.12637. Epub 2016 Sep 27. Review.

24.

Population pharmacokinetics and dosing recommendations for the use of deferiprone in children younger than 6 years.

Bellanti F, Del Vecchio GC, Putti MC, Maggio A, Filosa A, Cosmi C, Mangiarini L, Spino M, Connelly J, Ceci A, Della Pasqua O; Consortium DEferiprone Evaluation in Paediatrics (DEEP).

Br J Clin Pharmacol. 2017 Mar;83(3):593-602. doi: 10.1111/bcp.13134. Epub 2016 Nov 6.

25.

Pharmacotherapy in pediatric epilepsy: from trial and error to rational drug and dose selection - a long way to go.

van Dijkman SC, Alvarez-Jimenez R, Danhof M, Della Pasqua O.

Expert Opin Drug Metab Toxicol. 2016 Oct;12(10):1143-56. doi: 10.1080/17425255.2016.1203900. Epub 2016 Jul 21. Review.

PMID:
27434782
26.
27.

Pharmacology-based toxicity assessment: towards quantitative risk prediction in humans.

Sahota T, Danhof M, Della Pasqua O.

Mutagenesis. 2016 May;31(3):359-74. doi: 10.1093/mutage/gev081. Epub 2016 Mar 12. Review.

PMID:
26970519
28.

Sampling Optimization in Pharmacokinetic Bridging Studies: Example of the Use of Deferiprone in Children With β-Thalassemia.

Bellanti F, Di Iorio VL, Danhof M, Della Pasqua O.

J Clin Pharmacol. 2016 Sep;56(9):1094-103. doi: 10.1002/jcph.708. Epub 2016 Apr 1.

PMID:
26785826
29.

Model-Based Optimisation of Deferoxamine Chelation Therapy.

Bellanti F, Del Vecchio GC, Putti MC, Cosmi C, Fotzi I, Bakshi SD, Danhof M, Della Pasqua O.

Pharm Res. 2016 Feb;33(2):498-509. doi: 10.1007/s11095-015-1805-0. Epub 2015 Nov 10.

30.

Assessment of Interspecies Differences in Drug-Induced QTc Interval Prolongation in Cynomolgus Monkeys, Dogs and Humans.

Dubois VF, de Witte WE, Visser SA, Danhof M, Della Pasqua O; Cardiovascular Safety Project Team; TI Pharma PKPD Platform.

Pharm Res. 2016 Jan;33(1):40-51. doi: 10.1007/s11095-015-1760-9. Epub 2015 Nov 9.

31.

Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers.

Antunes Nde J, Wichert-Ana L, Coelho EB, Della Pasqua O, Alexandre Junior V, Takayanagui OM, Tozatto E, Marques MP, Lanchote VL.

Eur J Clin Pharmacol. 2016 Feb;72(2):195-201. doi: 10.1007/s00228-015-1970-4. Epub 2015 Oct 30.

PMID:
26514967
32.

Biomarker exposure-response relationships as the basis for rational dose selection: Lessons from a simulation exercise using a selective COX-2 inhibitor.

Taneja A, Oosterholt SP, Danhof M, Della Pasqua O.

J Clin Pharmacol. 2016 May;56(5):609-21. doi: 10.1002/jcph.629. Epub 2015 Dec 27.

PMID:
26331692
33.

Generating Virtual Patients by Multivariate and Discrete Re-Sampling Techniques.

Teutonico D, Musuamba F, Maas HJ, Facius A, Yang S, Danhof M, Della Pasqua O.

Pharm Res. 2015 Oct;32(10):3228-37. doi: 10.1007/s11095-015-1699-x. Epub 2015 May 21.

34.

Integration of PKPD relationships into benefit-risk analysis.

Bellanti F, van Wijk RC, Danhof M, Della Pasqua O.

Br J Clin Pharmacol. 2015 Nov;80(5):979-91. doi: 10.1111/bcp.12674. Epub 2015 Jul 29. Review.

35.

Model-based prediction of the acute and long-term safety profile of naproxen in rats.

Sahota T, Sanderson I, Danhof M, Della Pasqua O.

Br J Pharmacol. 2015 Aug;172(15):3861-74. doi: 10.1111/bph.13167. Epub 2015 Jun 29.

36.

The impact of composite AUC estimates on the prediction of systemic exposure in toxicology experiments.

Sahota T, Danhof M, Della Pasqua O.

J Pharmacokinet Pharmacodyn. 2015 Jun;42(3):251-61. doi: 10.1007/s10928-015-9413-5. Epub 2015 Apr 14.

37.

Busulfan dosing algorithm and sampling strategy in stem cell transplantation patients.

de Castro FA, Piana C, Simões BP, Lanchote VL, Della Pasqua O.

Br J Clin Pharmacol. 2015 Oct;80(4):618-29. doi: 10.1111/bcp.12648. Epub 2015 Jul 22.

38.

Rational use of medicines in older adults: Can we do better during clinical development?

Saeed MA, Vlasakakis G, Della Pasqua O.

Clin Pharmacol Ther. 2015 May;97(5):440-3. doi: 10.1002/cpt.87. Epub 2015 Apr 10.

PMID:
25676612
39.

On the role of concentration-effect relationships in safety pharmacology: only the dose makes a drug not to be poison!

Della Pasqua O.

Br J Clin Pharmacol. 2015 Jun;79(6):1042-3. doi: 10.1111/bcp.12593. No abstract available.

40.

Prediction of disease progression, treatment response and dropout in chronic obstructive pulmonary disease (COPD).

Musuamba FT, Teutonico D, Maas HJ, Facius A, Yang S, Danhof M, Della Pasqua O.

Pharm Res. 2015 Feb;32(2):617-27. doi: 10.1007/s11095-014-1490-4. Epub 2014 Sep 18.

41.

Model-based evaluation of drug-induced QTc prolongation for compounds in early development.

Dubois VF, Yu H, Danhof M, Della Pasqua O; Cardiovascular Safety Project Team and TI Pharma PKPD Platform.

Br J Clin Pharmacol. 2015 Jan;79(1):148-61. doi: 10.1111/bcp.12482.

42.

Population pharmacokinetics of deferiprone in healthy subjects.

Bellanti F, Danhof M, Della Pasqua O.

Br J Clin Pharmacol. 2014 Dec;78(6):1397-406. doi: 10.1111/bcp.12473.

43.

The role of concentration-effect relationships in the assessment of QTc interval prolongation.

France NP, Della Pasqua O.

Br J Clin Pharmacol. 2015 Jan;79(1):117-31. doi: 10.1111/bcp.12443. Review.

44.

Integrative knowledge management to enhance pharmaceutical R&D.

Marti-Solano M, Birney E, Bril A, Della Pasqua O, Kitano H, Mons B, Xenarios I, Sanz F.

Nat Rev Drug Discov. 2014 Apr;13(4):239-40. doi: 10.1038/nrd4290.

PMID:
24687050
45.

Model-based analysis of thromboxane B₂ and prostaglandin E₂ as biomarkers in the safety evaluation of naproxen.

Sahota T, Sanderson I, Danhof M, Della Pasqua O.

Toxicol Appl Pharmacol. 2014 Aug 1;278(3):209-19. doi: 10.1016/j.taap.2014.03.010. Epub 2014 Mar 22.

PMID:
24667227
46.

Implications of pharmacogenetics for the therapeutic use of antiepileptic drugs.

Piana C, Antunes Nde J, Della Pasqua O.

Expert Opin Drug Metab Toxicol. 2014 Mar;10(3):341-58. doi: 10.1517/17425255.2014.872630. Epub 2014 Jan 25. Review.

PMID:
24460510
47.

Influence of covariate distribution on the predictive performance of pharmacokinetic models in paediatric research.

Piana C, Danhof M, Della Pasqua O.

Br J Clin Pharmacol. 2014 Jul;78(1):145-57. doi: 10.1111/bcp.12322.

48.

Translational pharmacology: from animal to man and back.

Della Pasqua O.

Drug Discov Today Technol. 2013 Sep;10(3):e315-7. No abstract available.

PMID:
24179994
49.

Cardiovascular disease: the other face of diabetes.

Vlasakakis G, Della Pasqua O.

CPT Pharmacometrics Syst Pharmacol. 2013 Oct 23;2:e81. doi: 10.1038/psp.2013.57.

50.

Analysis of oxcarbazepine and the 10-hydroxycarbazepine enantiomers in plasma by LC-MS/MS: application in a pharmacokinetic study.

de Jesus Antunes N, Wichert-Ana L, Coelho EB, Della Pasqua O, Alexandre V Jr, Takayanagui OM, Tozatto E, Lanchote VL.

Chirality. 2013 Dec;25(12):897-903. doi: 10.1002/chir.22231. Epub 2013 Sep 30.

PMID:
24123382

Supplemental Content

Loading ...
Support Center